Acelyrin Overview
- Year Founded
-
2020
- Status
-
Acquired/Merged
- Employees
-
83
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$238M
Acelyrin General Information
Description
Acelyrin Inc is a late-stage clinical biopharmaceutical company. The clinical biopharma segment researches and develops treatments for diseases with pathology related to excess activation of the immune system. It is focused on providing patients with life-changing new treatment options by identifying, acquiring, and accelerating the development and commercialization of transformative medicines.
Contact Information
Website
www.acelyrin.comCorporate Office
- 4149 Liberty Canyon Road
- Agoura Hills, CA 91301
- United States
Corporate Office
- 4149 Liberty Canyon Road
- Agoura Hills, CA 91301
- United States
Acelyrin Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Merger/Acquisition | 21-May-2025 | $238M | Completed | Generating Revenue | ||
| 4. IPO | 05-May-2023 | Completed | Generating Revenue | |||
| 3. Later Stage VC (Series C) | 09-Sep-2022 | Completed | Clinical Trials - Phase 3 | |||
| 2. Early Stage VC (Series B) | 16-Nov-2021 | $250M | $258M | Completed | Clinical Trials - Phase 2 | |
| 1. Early Stage VC (Series A) | 09-Oct-2020 | $8M | $8M | Completed | Startup |
Acelyrin Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C | ||||||||
| Series B | ||||||||
| Series A | 8,000,000 | $0.000010 | 8% | $1 | $1 | 1x | $1 | 6.22% |
Acelyrin Comparisons
Industry
Financing
Details
Acelyrin Competitors (71)
One of Acelyrin’s 71 competitors is Protagonist Therapeutics, a Formerly VC-backed company based in Newark, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Protagonist Therapeutics | Formerly VC-backed | Newark, CA | ||||
| NovaBridge Biosciences | Formerly VC-backed | Rockville, MD | ||||
| Sarepta Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| Minerva Neurosciences | Formerly VC-backed | Burlington, MA | ||||
| Ayala Pharmaceuticals | Corporation | Wilmington, DE |
Acelyrin Patents
Acelyrin Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2025244076-A1 | Methods and compositions comprising lonigutamab for treating ted | Pending | 20-Mar-2024 | ||
| WO-2025207408-A1 | Methods and compositions comprising lonigutamab for treating ted | Pending | 20-Mar-2024 | ||
| WO-2025054498-A1 | Methods of treating hidradenitis suppurativa | Inactive | 08-Sep-2023 | ||
| WO-2025054491-A1 | Methods of treatment of psoriatic arthritis | Inactive | 08-Sep-2023 | ||
| WO-2025054497-A1 | Methods of treatment of uveitis | Inactive | 08-Sep-2023 | A61P27/02 |
Acelyrin Signals
Acelyrin Former Investors (13)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Access Biotechnology | Corporate Venture Capital | Minority | ||
| Cowen Healthcare Investments | Venture Capital | Minority | ||
| Decheng Capital | Venture Capital | Minority | ||
| General Atlantic | Growth/Expansion | Minority | ||
| Marshall Wace | Hedge Fund | Minority |
Acelyrin Acquisitions (1)
Acelyrin’s most recent deal was a Merger/Acquisition with ValenzaBio for . The deal was made on 04-Jan-2023.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| ValenzaBio | 04-Jan-2023 | Merger/Acquisition | Biotechnology |
Acelyrin ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
36.21 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,593
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
Acelyrin FAQs
-
When was Acelyrin founded?
Acelyrin was founded in 2020.
-
Where is Acelyrin headquartered?
Acelyrin is headquartered in Agoura Hills, CA.
-
What is the size of Acelyrin?
Acelyrin has 83 total employees.
-
What industry is Acelyrin in?
Acelyrin’s primary industry is Drug Discovery.
-
Is Acelyrin a private or public company?
Acelyrin is a Private company.
-
What is the current valuation of Acelyrin?
The current valuation of Acelyrin is .
-
What is Acelyrin’s current revenue?
The current revenue for Acelyrin is .
-
How much funding has Acelyrin raised over time?
Acelyrin has raised $1.1B.
-
Who are Acelyrin’s investors?
Access Biotechnology, Cowen Healthcare Investments, Decheng Capital, General Atlantic, and Marshall Wace are 5 of 13 investors who have invested in Acelyrin.
-
Who are Acelyrin’s competitors?
Protagonist Therapeutics, NovaBridge Biosciences, Sarepta Therapeutics, Minerva Neurosciences, and Ayala Pharmaceuticals are some of the 71 competitors of Acelyrin.
-
When was Acelyrin acquired?
Acelyrin was acquired on 21-May-2025.
-
Who acquired Acelyrin?
Acelyrin was acquired by Alumis (United States).
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process